Background Studies have shown that integrating anlotinib with programmed death 1 (PD-
1)/programmed death-ligand 1 (PD-L1) inhibitors enhances survival rates among …

Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third
or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from …

Background Anlotinib has demonstrated encouraging clinical outcomes in the treatment of
lung cancer, soft tissue sarcoma and thyroid carcinoma. Several clinical studies have shown …

Purpose Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors
plus chemotherapy have become the standard first line of treatment in patients with …

Background Clinical trials of anti-programmed cell death ligand 1 (PD-L1) inhibitor to treat
advanced non–small-cell lung cancer (aNSCLC) have permitted treatment beyond …

Purpose Programmed death or ligand‐1 (PD‐(L) 1) pathway inhibitors confer improved
survival as the first‐line treatment for advanced non‐small cell lung cancer (aNSCLC) in …

Purpose: PD-1 inhibitors are established agents in the management of non–small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine …

Simple Summary This study focuses on understanding the real-world impact of newly
introduced genetic tests and immune-based approaches on the survival of patients with non …

Background Programmed cell death 1 (PD‐1)/programmed cell death ligand (PD‐L1)
inhibitors plus chemotherapy (ICI+ Chemo) is the standard treatment for advanced non …

Abstract Background Evidence on PD-1/PD-L1-directed immune checkpoint inhibitor (ICI)
therapy for advanced non-small-cell lung cancer (NSCLC) is mainly based on clinical trials …